Compare Gilead Sciences, Inc. (GILD) vs Vanguard S&P 500 ETF (VOO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vanguard S&P 500 ETF — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Vanguard S&P 500 ETF trades at $714.58 (market cap $1.80T). The key difference: Vanguard S&P 500 ETF is far larger — about 9.9× Gilead Sciences, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vanguard S&P 500 ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vanguard S&P 500 ETF for 55 Days on average.
| GILD | VOO | |
|---|---|---|
Market Cap | $182.09B | $1.80T |
Volume | 4,960,247 | 4,660,398 |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $716.17 |
52-Week Low | $116.74 | $580.93 |
Typical Hold Time | 111 Days | 55 Days |
Enterprise Value | $205.15B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
VOO trades at $714.42, down 0.24% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF's dividend yield is modest, and recent news highlights its role in long-term wealth building amid expectations of slowing S&P 500 profit growth. Short interest increased 46.9% in September, indicating some bearish sentiment.
The outlook for VOO remains positive for buy-and-hold investors, supported by its low-cost exposure to the S&P 500. Risks include macroeconomic headwinds from potential Fed rate hikes and elevated short interest. Analyst consensus favors long-term holding, with the ETF seen as a core portfolio component for diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vanguard S&P 500 ETF
VOO is a foundational ETF that tracks the S&P 500 Index, providing exposure to 500 of the largest and most established companies in the United States. Renowned for its ultra-low expense ratio and tax efficiency, it serves as a core building block for long-term investors seeking to capture the total return of the U.S. large-cap market in a single, highly liquid vehicle.
Read more on VOO →
